Loading
Cedilla Therapeutics was a company that tried to make small-molecule drugs that change how stable cancer-driving proteins are. Its investor says it closed down in 2024.
Cedilla Therapeutics launched in April 2018 with $56.2 million in Series A funding from Third Rock Ventures, to discover small molecules that exploit insights into protein stability and to apply them to proteins that drive cancer and other diseases, working upstream of native protein degradation pathways. Third Rock Ventures says the company wound down operations in 2024. No named drug candidate was found in the sources read.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · From Third Rock Ventures, at launch | 2018 | $56M | biospace.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/